MetLife Investment Management LLC Has $2.24 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Posted by on Feb 27th, 2023

MetLife Investment Management LLC raised its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 2.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,101 shares of the company’s stock after buying an additional 917 shares during the period. MetLife Investment Management LLC owned about 0.05% of Intellia Therapeutics worth $2,244,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NTLA. Wipfli Financial Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $25,000. National Bank of Canada FI acquired a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $39,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Intellia Therapeutics by 462.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 866 shares of the company’s stock valued at $48,000 after purchasing an additional 712 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Intellia Therapeutics in the 1st quarter valued at $97,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Intellia Therapeutics by 36.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,072 shares of the company’s stock valued at $109,000 after purchasing an additional 552 shares during the last quarter. Institutional investors and hedge funds own 85.61% of the company’s stock.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $37.74 on Monday. The firm’s 50-day moving average is $38.40 and its 200-day moving average is $48.60. Intellia Therapeutics, Inc. has a 52-week low of $32.44 and a 52-week high of $103.06. The company has a market cap of $2.97 billion, a price-to-earnings ratio of -6.11 and a beta of 1.90.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last posted its quarterly earnings data on Thursday, February 23rd. The company reported ($1.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.40). Intellia Therapeutics had a negative net margin of 909.78% and a negative return on equity of 53.49%. The company had revenue of $13.60 million for the quarter, compared to the consensus estimate of $10.71 million. During the same quarter in the previous year, the firm posted ($1.09) EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Equities analysts predict that Intellia Therapeutics, Inc. will post -5.9 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. EF Hutton Acquisition Co. I reduced their price objective on shares of Intellia Therapeutics from $123.00 to $116.00 and set a “buy” rating for the company in a research note on Friday. Citigroup raised shares of Intellia Therapeutics from a “sell” rating to a “neutral” rating and reduced their price objective for the company from $48.00 to $39.00 in a research note on Tuesday, January 24th. Robert W. Baird reduced their price objective on shares of Intellia Therapeutics from $58.00 to $42.00 and set a “neutral” rating for the company in a research note on Friday. Wells Fargo & Company cut their target price on shares of Intellia Therapeutics from $135.00 to $120.00 and set an “overweight” rating for the company in a research report on Wednesday, January 4th. Finally, Chardan Capital cut their target price on shares of Intellia Therapeutics from $129.00 to $111.00 in a research report on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $89.28.

Insider Activity at Intellia Therapeutics

In related news, CFO Glenn Goddard sold 2,427 shares of the company’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $90,308.67. Following the sale, the chief financial officer now owns 15,404 shares of the company’s stock, valued at $573,182.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, EVP Laura Sepp-Lorenzino sold 2,508 shares of the company’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total value of $93,322.68. Following the sale, the executive vice president now owns 19,959 shares of the company’s stock, valued at $742,674.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Glenn Goddard sold 2,427 shares of the company’s stock in a transaction dated Wednesday, January 4th. The shares were sold at an average price of $37.21, for a total transaction of $90,308.67. Following the completion of the sale, the chief financial officer now directly owns 15,404 shares in the company, valued at approximately $573,182.84. The disclosure for this sale can be found here. Insiders have sold a total of 11,608 shares of company stock valued at $431,934 over the last quarter. 3.90% of the stock is owned by company insiders.

Intellia Therapeutics Profile

(Get Rating)

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.

Read More

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.